NCT00002900
SWOG-9342 Chemotherapy in Treating Women Enrolled in the SWOG-8897 Clinical Trial
COMPLETED
NCT00002900
OBSERVATIONAL
A STUDY OF THE LATE CARDIAC EFFECTS OF TWO DIFFERENT ADJUVANT CHEMOTHERAPY REGIMENTS IN WOMEN WITH NODE NEGATIVE BREAST CANCER TREATED ON SWOG-8897
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: This clinical trial is studying the effect of chemotherapy on heart function in treating women who have breast cancer with negative axillary lymph nodes and who are undergoing treatment on the SWOG-8897 clinical trial.
DISEASE CHARACTERISTICS:
* Women registered on Arm I, II, III, or IV of protocol SWOG-8897 who have completed at least 1 course of assigned chemotherapy
* Completion of tamoxifen therapy not required
* Registration to current study required between 5.25-8 years or 10-11 years after randomization to protocol SWOG-8897
* Patients must be diagnosed disease-free with no prior recurrence after registration on protocol SWOG-8897
* Hormone receptor status:
* Not specified
PATIENT CHARACTERISTICS:
Age:
* 18 and over
Sex:
* Female
Menopausal status:
* Pre- and postmenopausal
Performance status:
* Not specified
Life Expectancy:
* At least 5 years
Hematopoietic:
* Not specified
Hepatic:
* Not specified
Renal:
* Not specified
Other:
* Pregnant or nursing women not eligible for nuclear medicine (MUGA) portion of study
* Fertile patients must use effective contraception during and for 1 month after MUGA
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* See Disease Characteristics
* No prior chemotherapy for second primary malignancy
Endocrine therapy:
* Not specified
Radiotherapy:
* No prior radiotherapy for second primary malignancy
Surgery:
* Not specified
Breast Cancer
Cardiac Toxicity
-
- Type: PROCEDURE
- Name: management of therapy complications
- Description:
- Arm Group Labels:
- SWOG Cancer Research Network